Sandoz Gmbh

John Morley

Martin List

Stefan Blarer

Zoltan L Kis

Andreas Rummelt

Ian D Chapman

Pulmonary administration of Ciclosporin in orthorhombic crystal form (designated 'CY-A/X-III'), e.g. for the treatment of obstructive or inflammatory airways disease, e.g. asthma, as well as crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form, processes for its preparation and its pharmaceutical use, e.g. for pulmonary administration. Pharmaceutical compositions comprising CY-A/X-III and crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form as well as Ciclosporin in solution in aerosol propellants are also provided.

Ciclosporin form for pulmonary administration

A compound of formula I ##STR1## wherein R.sub.1 is C.sub.1-4 alkyl, C.sub.3-4 alkenyl or (C.sub.3-5 cycloalkyl)-methyl, R.sub.2 is C.sub.1-4 alkyl, [hydroxy- or (C.sub.1-4 alkoxy)-substituted C.sub.1-3 alkyl]-methyl, (C.sub.3-5 cycloalkyl)-methyl, tetrahydrofuran 2-yl-methyl or 1,3-dioxolan-2-yl-methyl, R.sub.3 and R.sub.4 are each hydrogen, hydroxymethyl, methoxymethyl or N,N-dimethylcarbamoyloxymethyl, R.sub.5 is hydroxy or methoxy, R.sub.6 is hydrogen, hydroxy, methoxy or halogen and R.sub.7 is in the 2- or 3-position and is hydroxy, methoxy or halogen, or together with R.sub.5 is 3,4-methylendioxy, or together with R.sub.6 is 2,3-methylenedioxy and their physiologically-hydrolysable and -acceptable esters are useful in the treatment (symptomatic and prophylactic) of obstructive or inflammatory airways disease, in particular asthma, and disease characterised by or having an aetiology comprising morbid eosinophil accumulation or activation, e.g. hypereosinophilia.

Novel xanthine derivatives

New benz[b]pyranes and pyranopyridines of formula I, ##STR1## wherein the significances of substituents V, T, W, R.sub.3 to R.sub.5, R.sub.9, R.sub.10, m, X, Y and Z are given in claim 1 and their N-oxides and their salts and their use in the treatment of raised blood pressure in the treatment of vascular disorders and other disorders in which a reduction in tension of the smooth muscles is therapeutically useful, as well as in the treatment of hair loss and baldness. Further the compounds are useful in the treatment of asthma and obstructive disorders of the respiratory system as well as in the prophylactic treatment of obstructive or inflammatory airways disease, for example asthma, as well as novel pharmaceutical compositions comprising said K.sup.+ channel activators suitable for such use.

Growing community of inventors

Muttenz, Switzerland

John Morley